Encephalitis, Tick-Borne Clinical Trial
Official title:
Open-label Follow-up Study to Investigate the Seropersistence of TBE Antibodies and the Booster Response to a Tick-borne Encephalitis Vaccine in Children and Adolescents Aged 3 - 18 Years
The purpose of this study is to assess the seropersistence of TBE antibodies in children and
adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34
months after completion of primary immunization with FSME-IMMUN 0.25 ml (3 vaccinations
during the predecessor study 209), as well as the immune response to a booster vaccination
with FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml administered 36 months after the third
vaccination (in Study 209).
Protocol amendment of October 2006: The study has been prolonged for children and
adolescents who still showed highly positive TBE virus antibody concentrations at
approximately 3 years after the third vaccination and therefore did not receive a booster
vaccination at this time point. Further follow-up of TBE antibody persistence is now
included for these subjects at 46 and 58 months after the third vaccination (in Study 209),
as well as a booster vaccination offered at either 48 or 60 months after the third
vaccination (in Study 209), depending on individual TBE antibody levels.
Status | Completed |
Enrollment | 375 |
Est. completion date | November 2008 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 3 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Participated in Baxter study 209 and: - They and/or their parents / legal guardians understand the nature of the study and agree to its provisions - Written informed consent is available from the parents / legal guardians according to national law - Written informed assent is available from the child/adolescent according to age and capacity of understanding - They received the third vaccination with FSME-IMMUN 0.25 ml during the course of Baxter study 209 - Blood was drawn after their third vaccination during the course of Baxter study 209 - They showed an ELISA concentration > 126 VIE U/ml and / or a NT titer >=10 after the third vaccination in Baxter study 209 - They or their parents / legal guardians agree to keep a Subject Diary Exclusion Criteria: - Received any TBE vaccination since their third vaccination with FSME-IMMUN 0.25 ml - Have a history of infection with or vaccination against other flaviviruses (Dengue fever, yellow fever and / or Japanese B-encephalitis virus) since their third vaccination with FSME-IMMUN 0.25 ml - Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since their third vaccination with FSME-IMMUN 0.25 ml - Received a blood transfusion or immunoglobulins within 30 days of the first and second blood draw (as applicable) - Have a known or suspected problem with drug or alcohol abuse (> 4 liters wine / week or equivalent level of other alcoholic beverages) - Have participated in another Baxter vaccine study within the last six months (with the exception of follow-up studies) Subjects will not be eligible for booster vaccination if they: - Do not meet the inclusion / exclusion criteria - Are not clinically healthy, (i.e. the physician would have reservations vaccinating with a TBE vaccine outside the scope of a clinical trial) - Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions - Have shown an allergic reaction to one of the components of the vaccine since their third vaccination in Baxter study 209 - Have donated blood or plasma within 30 days of the booster vaccination if female of childbearing potential - are pregnant or breastfeeding before the booster vaccination (positive pregnancy test result at the medical examination before the booster vaccination) - Are simultaneously participating in another clinical trial including administration of an investigational product within six weeks prior to the booster vaccination until the end of the study Subjects who meet the inclusion/exclusion criteria, but have a febrile illness (body temperature >=38.0°C, measured orally) at the scheduled time of vaccination will not be vaccinated until their body temperature returns to normal. Subjects who received any vaccination within 4 weeks prior to the booster vaccination will not be vaccinated until an interval of four weeks has passed. If subjects received antipyretics within 4 hours prior to the intended TBE vaccination, the vaccination should be performed at a later time. Females of childbearing potential will only be vaccinated if they agree to employ adequate birth control measures from 4 weeks before the booster vaccination until the end of the study. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Austria | Grieskirchner Strasse 17 | Wels | Upper Austria |
Germany | Hauptstrasse 240 | Kehl | |
Poland | Niepubliczny ZOZ | Zamosc |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Austria, Germany, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Seropositivity rate measured by ELISA and/or NT according to Adner et al., 2001 at each available time point after the third vaccination in study 209 and separately at each available time point after the booster vaccination in this study | TBE virus antibody tests at pre-determined intervals with the last test at 21-35 days after the booster vaccination in this study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01031537 -
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
|
Phase 2 | |
Completed |
NCT00460486 -
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
|
Phase 3 | |
Completed |
NCT00161824 -
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
|
Phase 3 | |
Completed |
NCT00163540 -
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
|
Phase 4 | |
Completed |
NCT00161876 -
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
|
Phase 3 | |
Recruiting |
NCT03932448 -
Fever After Tick Bite Study
|
||
Completed |
NCT00311441 -
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
|
Phase 4 | |
Completed |
NCT00161954 -
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
|
Phase 4 | |
Completed |
NCT00163618 -
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
|
Phase 4 | |
Completed |
NCT00503529 -
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
|
Phase 4 | |
Completed |
NCT00840801 -
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
|
Phase 3 | |
Completed |
NCT00452621 -
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
|
Phase 4 | |
Completed |
NCT00311493 -
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
|
Phase 4 | |
Completed |
NCT00161850 -
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
|
Phase 2 | |
Completed |
NCT00161889 -
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
|
Phase 2 | |
Completed |
NCT00894686 -
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
|
Phase 4 | |
Completed |
NCT00161746 -
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
|
Phase 2/Phase 3 |